Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
167
projects in our pipeline
